Search research articles
Contact Us
Filters
Showing results (1-10 of 81) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
Roman Perez-Soler
Clinical Lung Cancer
|
January 11, 2005
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer
Roman Perez-Soler
Clinical Lung Cancer
|
January 24, 2007
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer
Roman Perez-Soler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer
Roman Perez-Soler
Targeted Oncology
|
May 20, 2009
Skin toxicities associated with epidermal growth factor receptor inhibitors
Tianhong Li, Roman Perez-Soler
Drugs
|
June 21, 2012
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
Bilal Piperdi, Roman Perez-Soler
Methods in Molecular Medicine
|
November 1, 2002
Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy
Missak Haigentz, Roman Perez-Soler
The Lancet. Oncology
|
January 6, 2018
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng, Roman Perez-Soler
Cancer
|
November 17, 2011
Mechanisms of resistance to vascular endothelial growth factor blockade
Shaad E Abdullah, Roman Perez-Soler
Oncology (Williston Park, N.Y.)
|
December 25, 2007
Clinical research of EGFR inhibitors and related dermatologic toxicities
Roman Perez-Soler, Eric Van Cutsem
Page
of 9
Search research articles
Search
Showing results (1-10 of 81) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
Roman Perez-Soler
Clinical Lung Cancer
|
January 11, 2005
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer
Roman Perez-Soler
Clinical Lung Cancer
|
January 24, 2007
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer
Roman Perez-Soler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer
Roman Perez-Soler
Targeted Oncology
|
May 20, 2009
Skin toxicities associated with epidermal growth factor receptor inhibitors
Tianhong Li, Roman Perez-Soler
Drugs
|
June 21, 2012
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
Bilal Piperdi, Roman Perez-Soler
Methods in Molecular Medicine
|
November 1, 2002
Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy
Missak Haigentz, Roman Perez-Soler
The Lancet. Oncology
|
January 6, 2018
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng, Roman Perez-Soler
Cancer
|
November 17, 2011
Mechanisms of resistance to vascular endothelial growth factor blockade
Shaad E Abdullah, Roman Perez-Soler
Oncology (Williston Park, N.Y.)
|
December 25, 2007
Clinical research of EGFR inhibitors and related dermatologic toxicities
Roman Perez-Soler, Eric Van Cutsem
Page
of 9